2023 Helen Walker Grant Recipient
August 1, 2024
Project title: Autophagy control of glycogen in skeletal muscle
This year, the AMDA was fortunate to receive 13 grant applications focusing on both clinical research and basic science. It has been a challenge to select one.
Dr. Wyant was chosen because he has embarked on a discovery project aimed at solving a missing piece of the puzzle: how does glycogen enter the lysosomes? A presumptive pathway for glycogen traffic to the lysosome is autophagy – a familiar term in Pompe disease research. In fact, one of the canonical images describing the disease illustrates glycogen transport to the lysosome in a vesicle (autophagosome) that is formed during autophagy. Although the concept of glycogen autophagy, called glycophagy, recently gained a lot of interest, the mechanism of muscle glycogen entrapment into the autophagosome has eluded the researchers for a long time.
The team developed a novel sophisticated approach to directly follow glycogen trafficking to the lysosome in skeletal muscle. The proposed study holds promise to identify a protein(s) that bind to glycogen and anchors it to the autophagosomal membrane. The implications of this discovery could be manipulated, so that less glycogen is delivered to the lysosomes, thus limiting damage to the muscle cells.
The application scored highest for novelty and scientific depth. We welcome Dr. Wyant and his team to the Pompe community.
OTHER NEWS
2018 Helen Walker Research Grant For Pompe Disease Now Accepting Applications
The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe Disease research. This grant opportunity was made possible by the 2018 Pull for Pompe, a private fundraiser held by the Precast Manufacturer’s Association of Texas...
Press Release: Amicus Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
CRANBURY, N.J., Sept. 10, 2018—Amicus Therapeutics, a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program AT-GAA for...
Press Release from Erasmus Medical Center: Making Muscle from Skin
Researchers from the Erasmus MC in Rotterdam, Netherlands, have succeeded in generating muscle cells from skin cells. This is significant as skin cells can be relatively easily obtained from a skin biopsy. The team developed a protocol to obtain pure muscle cells (ie...
2017 Helen Walker Research Grant For Pompe Disease Now Accepting Applications
The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe Disease research. This grant opportunity was made possible by the 2017 Pull for Pompe, a private fundraiser held by the Precast Manufacturer’s Association of Texas...
Valerion Initiates VAL-1221 Dosing in Patients with Pompe Disease
CONCORD, Mass., July 11, 2017—Valerion Therapeutics, a clinical-stage biotechnology company that specializes in the development of therapies for orphan genetic diseases, today announced that it has initiated dosing in a Phase 1/2 clinical trial evaluating VAL-1221 in...
In Memory of Henri Termeer
he AMDA was saddened to learn of the sudden passing of Henri Termeer, former CEO of Genzyme. We have known and worked with Henri since the late-90s through his role as the CEO of Genzyme. We will never forget how he always took the time to talk to patients and their...
Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Phase 1/2 Study
Excerpt . . . . CRANBURY, N.J., May 15, 2017 —Amicus Therapeutics today announced positive functional data from initial patients in a global Phase 1/2 study (ATB200-02) to investigate ATB200/AT2221 in patients with Pompe disease. Patients who completed six months of...
2017 PCMA of Texas Pull for Pompe!
The AMDA is excited to announce that the 2017 PCMA of Texas Pull for Pompe will take place on Saturday, March 25th at the National Shooting Complex in San Antonio, Texas! This is the 7th Annual Pull for Pompe hosted by the PCMA of Texas. The Pull for Pompe clay...
2016 Helen Walker Research Grant Awarded
The seventh annual AMDA Research Grant (the 2016 Helen Walker Research Grant) was awarded to Dr. Frédéric Lofaso with the Hôpital Raymond Poincaré in France for his Project: “Acid Maltase Deficiency Myopathy Follow-Up.” The aim of this project is to improve the...
Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy
Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease Cambridge, Mass. – November 4, 2016 - Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been...
Acid Maltase Deficiency Association
If you are interested in learning more about Pompe Disease and would like to make a contribution in support of necessary research, please contact us at:
info@amda-pompe.org
AMDA
PO Box 700248
San Antonio, Texas 78270 USA